FDA Approves Xacduro for Difficult-to-Treat
Bacterial Pneumonia

2023-05-30

上市批准优先审批快速通道合格传染病产品临床结果

TUESDAY, May 30, 2023 -- The U.S. Food and Drug Administration has approved Xacduro (sulbactam for injection; durlobactam for injection) as a new treatment for

hospital-acquired bacterial pneumonia

and

ventilator-associated bacterial pneumonia

caused by Acinetobacter baumannii-calcoaceticus complex (A. baumannii).

Xacduro is administered via intravenous infusion and consists of sulbactam, a drug structurally related to penicillin, and durlobactam. It was approved under fast track, priority review.

The approval was based upon a multicenter active-controlled, open-label (investigator-unblinded, assessor-blinded), noninferiority clinical trial in 177 hospitalized adults with

pneumonia

caused by carbapenem-resistant A. baumannii. Nineteen percent of patients receiving Xacduro died versus 32 percent of those who received colistin. The most common adverse reaction associated with Xacduro was

liver function test abnormalities

"The FDA is dedicated to supporting the development of safe and effective treatment options for

infections

caused by difficult-to-treat bacteria like Acinetobacter baumannii-calcoaceticus complex," Peter Kim, M.D., director of the Division of Anti-Infectives in the FDA Center for Drug Evaluation and Research, said in a statement. "Today's approval helps address a high unmet medical need by providing an additional treatment option for some of the sickest patients in our nation's hospitals."